Discover how MaxCyte Inc (MXCT) achieved significant revenue increases and strategic advancements in the first quarter of 2024.
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?